Investor News Source

Avalon GloboCare Reaches 'Major Clinical Milestone' by Dosing Its First Patients

Full Interview With CEO Dr. David Jin


Rochester, NY -- (ReleaseWire) -- 02/20/2020 --Full interview: Avalon GloboCare reaches 'major clinical milestone' by dosing its first patient.

Watch the Full Interview Here : Click Here to Watch The Interview With CEO Dr. David Jin

Avalon GloboCare Corp CEO Dr. David Jin tells Proactive the New Jersey-based company has reached a 'major clinical milestone' by beginning the first-in-human Phase I clinical trial of its flagship AVA-001 therapy in China to treat relapsed/refractory B-cell malignancies, including B-cell lymphoblastic leukemia and non-Hodgkin's Lymphoma.

Dr. Jin says the clinical trial is being conducted at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China, which he says is the world's single largest CAR-T treatment network with over 600 patients.

About Avalon GloboCare Corp
Avalon GloboCare Corp. is a clinical-stage, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of in vitro diagnostics (''liquid biopsy''), immune effector cell therapy (including CAR-T/CAR-NK), and regenerative therapeutics. For more information about Avalon GloboCare, please visit

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728

Source Link:

We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on this page unless you can afford to lose your entire investment. InvestorNewsSource and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. InvestorNewsSource is compensated by third party shareholders to feature certain companies. These third parties may have shares and may liquidate the company's shares which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Investor News Source may, from time to time, purchase shares of public companies that we have been compensated to feature or profile in the open market and Investor News Source does this at fair market value. Release of Liability: Through use of this advertisement page viewing or using you agree to hold InvestorNewsSource its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the Information. This is not a solicitation to buy stock.